A phase I trial to assess the tolerability and efficacy of IMC-mage1 in patients with multiple myeloma.

Trial Profile

A phase I trial to assess the tolerability and efficacy of IMC-mage1 in patients with multiple myeloma.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 01 May 2012

At a glance

  • Drugs IMC mage1 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Immunocore
  • Most Recent Events

    • 01 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top